• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of Empagliflozin on Multiple Biomarkers in Heart Failure: Insights From the Empire Heart Failure Trial.

作者信息

Jensen Jesper, Omar Massar, Kistorp Caroline, Tuxen Christian, Poulsen Mikael Kjær, Faber Jens, Køber Lars, Gustafsson Finn, Møller Jacob Eifer, Schou Morten

机构信息

Department of Cardiology (J.J., M.S.), Herlev and Gentofte University Hospital, Denmark.

Department of Cardiology, Odense University Hospital, Denmark (M.O., M.K.P., J.E.M.).

出版信息

Circ Heart Fail. 2022 Aug;15(8):e009333. doi: 10.1161/CIRCHEARTFAILURE.121.009333. Epub 2022 Apr 21.

DOI:10.1161/CIRCHEARTFAILURE.121.009333
PMID:35973031
Abstract
摘要

相似文献

1
Effect of Empagliflozin on Multiple Biomarkers in Heart Failure: Insights From the Empire Heart Failure Trial.恩格列净对心力衰竭多种生物标志物的影响：来自帝国心力衰竭试验的见解
Circ Heart Fail. 2022 Aug;15(8):e009333. doi: 10.1161/CIRCHEARTFAILURE.121.009333. Epub 2022 Apr 21.
2
Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).恩格列净治疗心力衰竭的代谢效应：一项随机、双盲、安慰剂对照试验（Empire HF Metabolic）
Circulation. 2021 Jun;143(22):2208-2210. doi: 10.1161/CIRCULATIONAHA.120.053463. Epub 2021 Jun 1.
3
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).恩格列净对射血分数降低的心力衰竭合并 2 型糖尿病或糖尿病前期患者左心室容积的影响（SUGAR-DM-HF）。
Circulation. 2021 Feb 9;143(6):516-525. doi: 10.1161/CIRCULATIONAHA.120.052186. Epub 2020 Nov 13.
4
Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?依帕列净对心力衰竭斑马鱼模型中心脏生物标志物的影响：EMPA-REG OUTCOME 试验的线索？
Mol Cell Biochem. 2017 Sep;433(1-2):97-102. doi: 10.1007/s11010-017-3018-9. Epub 2017 Apr 8.
5
The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).恩格列净对心力衰竭患者生长分化因子 15 的影响：一项随机对照试验（Empire HF Biomarker）。
Cardiovasc Diabetol. 2022 Feb 27;21(1):34. doi: 10.1186/s12933-022-01463-2.
6
Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.钠-葡萄糖协同转运蛋白 2 抑制剂恩格列净的直接心脏作用可改善心肌氧化磷酸化并减轻压力超负荷性心力衰竭。
J Am Heart Assoc. 2021 Mar 16;10(6):e018298. doi: 10.1161/JAHA.120.018298. Epub 2021 Mar 13.
7
The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.钠-葡萄糖协同转运蛋白 2 抑制剂恩格列净可减轻高血压性心力衰竭大鼠的心肌纤维化并改善心室血液动力学。
Cardiovasc Diabetol. 2019 Apr 1;18(1):45. doi: 10.1186/s12933-019-0849-6.
8
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.恩格列净对心力衰竭患者估算细胞外液量、估算血浆量和肾小球滤过率的影响（Empire HF Renal）：一项双盲、随机、安慰剂对照试验的预先指定亚研究。
Lancet Diabetes Endocrinol. 2021 Feb;9(2):106-116. doi: 10.1016/S2213-8587(20)30382-X. Epub 2020 Dec 22.
9
Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.恩格列净可降低广泛心力衰竭结局的风险，无论基线时的心力衰竭状态如何。
Eur J Heart Fail. 2019 Mar;21(3):386-388. doi: 10.1002/ejhf.1419. Epub 2019 Feb 14.
10
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.恩格列净通过增强心肌能量代谢改善非糖尿病心力衰竭的不良左心室重构。
J Am Coll Cardiol. 2019 Apr 23;73(15):1931-1944. doi: 10.1016/j.jacc.2019.01.056.

引用本文的文献

1
Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial.恩格列净改善2型糖尿病合并冠状动脉疾病患者的高敏心肌肌钙蛋白I和高密度脂蛋白胆固醇：EMPA-CARD试验的事后分析
J Diabetes Metab Disord. 2023 Sep 22;22(2):1723-1730. doi: 10.1007/s40200-023-01305-2. eCollection 2023 Dec.
2
Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure.达格列净与糖尿病合并心力衰竭患者心脏生物标志物及心脏重塑之间的关联
Life (Basel). 2023 Aug 20;13(8):1778. doi: 10.3390/life13081778.